Morningstar

CREATE Medicines Demonstrates Complete B Cell Depletion and Repeatable Dosing in Non-human Primates with In Vivo CAR-T Platform

Industry-leading non-human primate (NHP) data validates CREATE's differentiated receptor design, targeted RNA-LNP platform, and ability to repeat dose Clinical entry planned H2 2026 CAMBRIDGE, Mass., ...
EurekAlert!

B cell targeted CAR-T therapy for autoimmune diseases

Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with ...
Kaleido Scope

Transcription factor T-bet regulates memory B cell subsets

However, details of the intervening steps, as researchers have learned in the past 65 years, are quite complex — certain cells carry the flu antigen to the immune system, specific immune cells respond ...
Healio

‘Complete eradication’ of B cells drives remission after autoimmune CAR T-cell therapy

Please provide your email address to receive an email when new articles are posted on . A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the ...